ELR+ CXC chemokines and their receptors (CXC chemokine receptor 1 and CXC chemokine receptor 2) as new therapeutic targets

被引：205

作者：

Bizzarri, Cinzia

Beccari, Andrea Rosario

Bertini, Riccardo

Cavicchia, Michela Rita

Giorgini, Simona

Allegretti, Marcello

机构：

[1] Dompe Pharma SPA, Dompe Res Ctr, I-67100 Laquila, Italy

[2] Regina Elena Inst Canc Res, Expt Chemotherapy Lab, Rome, Italy

来源：

PHARMACOLOGY & THERAPEUTICS | 2006年 / 112卷 / 01期

关键词：

ELR+ CXC chemokines; ischaemia/reperfusion injury; bronchiolitis obliterans syndrome; tumor progression; CXCR1/2; antagonists; non-competitive allosteric inhibitors;

D O I：

10.1016/j.pharmthera.2006.04.002

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

ELR+ CXC chemokines, by direct interaction with their cell surface receptors CXC chemokine receptor 1 (CXCR1) and CXC chemokine receptor 2 (CXCR2), are believed to be crucially involved in the direct migration and activation of leukocytes. ELR+ CXC chemokines are supposed to play a key role in several inflammatory diseases and this makes ELR+ CXC chemokines and their receptors attractive therapeutic targets. The first aim of this review is to discuss the potential pathological role of ELR+ CXC chemokines in different pathologies, including ulcerative colitis (UC), ischaemia/reperfusion injury (RI), bronchiolitis obliterans syndrome (BOS) and tumor progression. Moreover, the most recently described inhibitors of ELR+ CXC chemokines and their therapeutic indications will be reviewed. Finally, the mode of action and the potential therapeutical use of reparixin, a new potent and selective inhibitor of CXCR1/2 activity, and its chemical derivatives are also discussed. (c) 2006 Elsevier Inc. All rights reserved.

引用

页码：139 / 149

页数：11

共 123 条

[1] The CXC chemokine receptor 2, CXCR2, is the putative receptor for ELR+ CXC chemokine-induced angiogenic activity [J].